News

Citi Adjusts Marico's Price Target, Maintains Buy Rating

Citi Adjusts Marico's Price Target, Maintains Buy Rating

Citi Adjusts Marico's Price Target, Maintains Buy Rating

In a recent update, financial services giant Citi has revised its price target for Marico Ltd (MRCO:IN), bringing it down to INR750 from the previous INR765, while reaffirming a Buy rating on the company's stock. This adjustment is in response to Marico's recent performance, particularly its second-quarter consolidated revenue growth of 8% compared to the same period last year, primarily fueled by a 5% increase in volume within its core business in India.

Marico's essential product lines, including popular brands like Parachute and Saffola oils, have shown promising growth trends. The company has experienced a positive shift in volume and pricing, despite some areas experiencing revenue declines. Specifically, the value-added hair oils segment encountered an 8% decrease in revenue compared to the previous year, attributed to challenges such as reduced consumption in various categories.

Despite these challenges, Citi forecasts continued growth for the Parachute brand propelled by favorable trends in market formalization and recent price hikes of 4% for Parachute and 15% for Saffola oils. The company's food products and premium personal care segments are additionally outpacing overall market growth, thanks to innovative approaches and premiumization strategies that appeal to consumers.

However, it is worth noting that Citi anticipates Marico may face some profit pressure in the fiscal year 2025 due to escalating input costs. Nevertheless, the impact on earnings before interest, taxes, depreciation, and amortization (EBITDA) margins for the second half of the fiscal year is expected to be less dramatic.

Marico's management team has indicated a positive outlook, expecting a 50 basis points improvement year-over-year, despite some demand slowdown in urban locales. The company sees potential upsides from initiatives that aim to enhance distributor returns and expand their reach through Project SETU, designed to improve direct store engagement and increase product assortments available to consumers. These strategic steps have reinforced Citi's affirmation of its Buy rating based on the sustainable growth potential identified.

Financial Health and Market Position

In addition to Citi's assessment, recent insights can paint a fuller picture of Marico Ltd (MRCO:IN) as a compelling player in the market. The company's remarkable financial resilience is highlighted by its latest figures. In the last analyzed twelve months culminating in Q2 2025, Marico posted revenue of approximately $1,194.72 million, aligned with the previously mentioned 8% year-over-year growth.

Another indicator of Marico's strong market strategy is its gross profit margin, currently at an impressive 50.66%. This figure underscores the company’s robust pricing strategies and efficient cost management practices, proving particularly relevant in light of concerns over future profitability due to rising input costs.

Moreover, it's essential to mention that Marico has maintained a healthier financial condition by holding more cash than debt on its balance sheet. This strong liquidity position grants the company flexibility to tackle challenges and invest in its growth initiatives, further enhancing its innovation and premiumization strategies.

Marico's valuation metrics also draw interest; it is currently trading at a price-to-earnings (P/E) ratio of 53.09, indicating investor confidence in the company's future performance and growth potential. This high earnings multiple suggests that investors expect significant returns, likely considering the benefits from initiatives like Project SETU alongside the upward trend in its core business.

Conclusion

In conclusion, while recent adjustments to Marico's price target can be seen as a cautious take given current market dynamics, the underlying fundamentals indicate that the company remains well-positioned for continued success. With strategic initiatives aimed at enhancing growth, Marico's trajectory in the competitive marketplace seems optimistic, with the potential for maintaining its market leadership.

Frequently Asked Questions

What is the new price target for Marico set by Citi?

Citi has adjusted its price target for Marico to INR750 from the previous INR765.

What factors contributed to Marico's performance in the last quarter?

Marico's 8% year-over-year revenue growth was mainly driven by a 5% increase in volume across its core business.

What are some of Marico's key product lines?

Marico is known for its flagship products, such as Parachute oils and Saffola cooking oils.

How is Marico addressing profitability pressures?

The company is implementing various initiatives, including Project SETU, to enhance distributor returns and broaden its market reach.

What does Marico's financial health look like?

Marico has a strong financial position, highlighted by a gross profit margin of 50.66% and more cash than debt on its balance sheet.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 139

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 250

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 254

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 353

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 155

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 321

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 143

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 313

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Total Voting Rights: A Crucial Overview

Updated Category News Views 192

Insights into Total Voting Rights and Capital Octopus AIM VCT plc is a company that regularly updates its shareholders regarding vital information, including total voting rights and capital structure. Current Share Capital Details As of the latest disclosure period, Octopus AIM VCT plc has an issued share capital comprising 223,655,160 Ordinary shares, each valued at 1...

Continue Reading
Understanding Market Sentiment for Bio-Techne's Stock

Updated Category News Views 130

Analyzing Bio-Techne's Market Position Bio-Techne (NYSE: TECH) has recently seen an increase in the short percent of float, now standing at 29.12% since its last report. This translates to approximately 5.08 million shares sold short, making up 3.68% of all available regular shares for trading. With the current trading volume, it would typically take about 2.66 days for...

Continue Reading
Innovative Developments in Wound Care by Kane Biotech Inc.

Updated Category News Views 120

Advancements in Wound Care from Kane Biotech Inc. WINNIPEG, Manitoba — Kane Biotech Inc. (TSX-V:KNE) is making headlines with groundbreaking clinical and scientific advancements in wound care. The company recently showcased its innovative data during the Innovations in Wound Healing Annual Meeting, an event dedicated to revolutionizing treatment in this critical field....

Continue Reading
Senior Helpers Achieves Recognition as a Leading Franchise

Updated Category News Views 178

Senior Helpers Achieves Recognition as a Leading Franchise Independent Survey Shows Franchise Owners Are Highly Satisfied with Senior Helpers' Support and Overall Performance Senior Helpers has recently been awarded the title of a Top Franchise for 2025 by Franchise Business Review (FBR). This year marks a significant milestone as it is FBR's 20th year of recognizing...

Continue Reading
Bearish Moves: What Big Players Think of Super Micro Computer

Updated Category News Views 232

Diving into Super Micro Computer's Options Landscape You gotta love this market, right? Sometimes it’s a real gut check, and right now, Super Micro Computer (NASDAQ:SMCI) is at the forefront of some, let’s say, interesting options activity. Financial giants are making bearish moves—like, big-time bearish. Our look into the options history for good ol' SMCI shook out...

Continue Reading